4.5 Article Proceedings Paper

TOR on the brain

Journal

EXPERIMENTAL GERONTOLOGY
Volume 46, Issue 2-3, Pages 155-163

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exger.2010.08.030

Keywords

Rapamycin; TOR; Neurodegeneration; Alzheimer's disease; Huntington's disease; Parkinson's disease

Funding

  1. NIA NIH HHS [T32 AG000057, AG033373-03, AG035336-02, R01 AG035336, T32 AG 00057, R01 AG033373] Funding Source: Medline

Ask authors/readers for more resources

Signaling by target of rapamycin (mTOR in mammals) has been shown to modulate lifespan in several model organisms ranging from yeast to mice. In mice, reduced mTOR signaling by chronic rapamycin treatment leads to life span extension, raising the possibility that rapamycin and its analogs may benefit the aging brain and serve as effective treatments of age-related neurodegenerative diseases. Here, we review mTOR signaling and how neurons utilize mTOR to regulate brain function, including regulation of feeding, synaptic plasticity and memory formation. Additionally, we discuss recent findings that evaluate the mechanisms by which reduced mTOR activity might benefit the aging brain in normal and pathological states. We will focus on recent studies investigating mTOR and Alzheimer's disease, Parkinson's disease, and polyglutamine expansion syndromes such as Huntington's disease. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available